OXPHOS inhibitors for treatment of cancer

By using oxidative phosphorylation (OXPHOS) inhibitors to target the metabolic pathways of cancer cells, the treatment difficulties of recurrent and refractory cancers are solved, and effective control and survival of recurrent cancers are achieved.

CN119013019APending Publication Date: 2024-11-22IMMUNOMET THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033150.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-16
Filing Date
2023-02-16
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing cancer treatments are difficult to effectively treat recurrent and refractory cancers, especially because cancer cells can survive and relapse through metabolic pathways other than oxidative phosphorylation (OXPHOS).

Method used

Using oxidative phosphorylation (OXPHOS) inhibitors as a therapeutic method, selectively kill OXPHOS-dependent cancer cells through the unique metabolic pathway of targeting cancer cells, and combining other therapeutic agents to target OXPHOS-dependent cancer cells to prevent recurrence. .

Benefits of technology

Effectively treat recurrent and refractory cancers, prolong patient survival, improve treatment effects, reduce side effects, and enhance the therapeutic effect on specific types of cancers such as pancreatic ductal adenocarcinoma, BRAF mutant melanoma and castration-resistant prostate cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005075466180000011
    Figure BDA0005075466180000011
  • Figure BDA0005075466180000061
    Figure BDA0005075466180000061
  • Figure FDA0005075466170000011
    Figure FDA0005075466170000011
Patent Text Reader

Abstract

The present invention features a method of treating cancer in a subject wherein the method comprises administering to the subject an oxidative phosphorylation (OXPHOS) inhibitor, and wherein the cancer is refractory or recurrent for first-line treatment.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Priority declaration

[0002] This application claims the benefit of the filing date of U.S. Provisional Application No. 63 / 268,111, filed on February 16, 2022, the contents of which are hereby incorporated by reference in their entirety. Technical Field

[0003] Generally, the present invention relates to methods of treating cancer in a subject in need thereof with an inhibitor of oxidative phosphorylation (OXPHOS). The present invention also relates to treating refractory or recurrent cancer in a subject in need thereof with an inhibitor of oxidative phosphorylation. Background Art

[0004] Cancer, a group of diseases caused by harmful, abnormal, uncontrolled and unwanted cell growth, occurs in a variety of tissues and organs, including breast, lung, bladder, colon, rectum, uterus, testicles, kidney, blood, lymphatic system, liver, bile duct, skin, pancreas, prostate, thyroid, brain and stomach. Approximately 10,000,000 people die from cancer each year worldwide. Current therapies for treating cancer may not be able to treat recurrent cancer. Therefore, there is a continuing need for improved therapies for treating cancer. Summary of the invention

[0005] The present invention provides a method for treating cancer by administering an oxidative phosphorylation (OXPHOS) inhibitor, wherein the cancer is refractory or recurrent. The present invention also provides a method for treating cancer using a compound of the following formula 1 or a pharmaceutically acceptable salt thereof

[0006]

[0007] In one aspect, the invention features a method of treating cancer in a subject, wherein the method comprises administering to the subject an oxidative phosphorylation (OXPHOS) inhibitor, and wherein the cancer is refractory or relapsed to first-line treatment.

[0008] In one embodiment, the first-line treatment is the standard of care for the cancer. In other embodiments, the cancer is a carcinoma, sarcoma, leukemia, or lymphoma. In another embodiment, the cancer is a solid tumor. In additional embodiments, the cancer is a metastatic cancer.

[0009] In some embodiments, the leukemia is acute lymphocytic leukemia, chronic lymphocytic leukemia, myeloid leukemia, or chronic myeloid leukemia. In some embodiments, the lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma. In other embodiments, the cancer is breast cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, rectal cancer, uterine cancer, vaginal cancer or vulvar cancer, testicular cancer, kidney cancer, liver cancer, bile duct cancer, cholangiocarcinoma, gallbladder cancer, melanoma, pancreatic cancer, pancreatic ductal adenocarcinoma, BRAF mutant metastatic melanoma, prostate cancer, castration-resistant prostate cancer, thyroid cancer, glioblastoma, endometrial cancer, ovarian cancer, cervical cancer, brain cancer, glioblastoma, liver cancer, colorectal cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, gynecological cancer, head and neck cancer, mesothelioma, myeloma, esophageal cancer, or gastric cancer.

[0010] In certain embodiments, the OXPHOS inhibitor is a compound of Formula 1 or a pharmaceutically acceptable salt thereof.

[0011] In some embodiments, the compound of formula 1 is formulated as a tablet or capsule. In other embodiments, the tablet or capsule is formulated for delayed release. In other embodiments, the tablet or capsule comprises an enteric coating. In some embodiments, the compound of formula 1 is administered at a dose of about 100 mg, 200 mg, 400 mg, 800 mg or 1200 mg per day. In a specific embodiment, the compound of formula 1 is administered at a dose of about 800 mg per day.

[0012] In other embodiments, the OXPHOS inhibitor is administered in combination with a second therapeutic compound.

[0013] In another aspect, the invention features a method of treating pancreatic ductal adenocarcinoma (PDAC), wherein the method comprises administering a pharmaceutical composition to a subject in need thereof at a therapeutically effective dose, and wherein the composition comprises a compound of Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

[0014] In one embodiment, the compound of formula 1 is administered in combination with gemcitabine and nab-paclitaxel (Abraxane).

[0015] In additional aspects, the invention features a method of treating BRAF mutant melanoma, wherein the method comprises administering a pharmaceutical composition to a subject in need thereof at a therapeutically effective dose, and wherein the composition comprises a compound of Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

[0016] In some embodiments, the compound of Formula 1 is administered in combination with encorafenib and bimetinib. In other embodiments, the BRAF mutant melanoma is metastatic. In some embodiments, the metastasis is metastasis to the central nervous system. In a specific embodiment, the metastasis is metastasis to the brain. In another embodiment of this aspect, the method includes the use of radiation and / or the administration of temozolomide.

[0017] In another aspect, the invention features a method of treating castration-resistant prostate cancer (CRPC), wherein the method comprises administering a pharmaceutical composition to a subject in need thereof at a therapeutically effective dose, and wherein the composition comprises a compound of Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

[0018] In some embodiments, the subject has not responded to at least one line of immunotherapy. In other embodiments, the compound of Formula 1 is administered in combination with a checkpoint inhibitor. In a specific embodiment, the checkpoint inhibitor is a PD-1 inhibitor.

[0019] In some embodiments, the pharmaceutically acceptable salt is a salt of an acid selected from the group consisting of formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid, trifluoroacetic acid, malic acid, maleic acid, malonic acid, fumaric acid, succinic acid, succinic acid monoamide, glutamic acid, tartaric acid, oxalic acid, citric acid, glycolic acid, glucuronic acid, ascorbic acid, benzoic acid, phthalic acid, salicylic acid, anthranilic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, dichloroacetic acid, aminooxyacetic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid, and boric acid.

[0020] In certain embodiments, the pharmaceutically acceptable salt is acetate.

[0021] In some embodiments, the subject is a human.

[0022] definition

[0023] In this application, unless otherwise clear from the context, (i) the term "a" may be understood as "at least one"; (ii) the terms "comprising" and "including" may be understood to cover the listed components or steps, whether presented alone or with one or more additional components or steps; and (iii) the term "about" may be understood to allow for standard deviations as known to those of ordinary skill in the art; and (iv) where ranges are provided, the endpoints are included.

[0024] As used herein, the term "about" means a value within the range of ±10% of the value following the term "about". References herein to "about" a value or parameter include (and describe) variations for the value or parameter itself. For example, descriptions involving "about X" include descriptions of "X".

[0025] As used herein, the term "administering" refers to administering a composition (e.g., a compound or formulation comprising an OXPHOS inhibitor) to a subject or system. Administration to an animal subject (e.g., to a human) can be by any appropriate route. For example, in some embodiments, administration can be intrabronchial (including by bronchial instillation), buccal, enteral, intradermal, intraarterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (including by intratracheal instillation), transdermal, vaginal, and vitreous.

[0026] An "effective amount" of a compound (e.g., an OXPHOS inhibitor) can vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the compound to elicit a desired response. A therapeutically effective amount encompasses an amount in which the therapeutically beneficial effects outweigh any toxic or deleterious effects of the compound. An effective amount also encompasses an amount sufficient to confer a benefit (e.g., a clinical benefit).

[0027] As used herein, the term "subject" or "participant" or "patient" refers to any organism to which a compound or composition according to the invention may be administered, for example, for experimental, diagnostic, preventive and / or therapeutic purposes. Typical subjects include any animal (e.g., mammals, such as dogs, mice, rats, rabbits, pigs, non-human primates and humans). Subjects may seek or need treatment, require treatment, are receiving treatment, will receive treatment in the future, or are people or animals who are cared for by trained professionals for a particular disease or condition.

[0028] As used herein, the term "treat, treated or treating" means therapeutic treatment and prophylactic or preventative measures, wherein the purpose is to prevent or slow down (mitigate) an undesirable physiological condition, disorder or disease, or to obtain a beneficial or desired clinical result. Beneficial or desired clinical results include, but are not limited to, relief of symptoms; mitigation of the extent of a condition, disorder or disease; a stable (i.e., non-deteriorating) state of a condition, disorder or disease; a delay or slowing of the onset of a condition, disorder or disease progression; an improvement or alleviation (whether partial or complete) of a detectable or undetectable condition, disorder or disease state; an improvement in at least one measurable physical parameter, which is not necessarily discernible by the subject; or an enhancement or improvement of a condition, disorder or disease. Treatment includes causing a clinically significant response without an excessive level of side effects. Treatment also includes extending survival time compared to the expected survival time if not receiving treatment.

[0029] As used herein, the term "checkpoint inhibitor" means an inhibitor of a protein that determines whether an immune cell targets a cell for destruction, i.e., a checkpoint protein. Cancer cells express proteins on their surface that bind to checkpoint proteins on T cells. The binding between ligands on the surface of cancer cells and checkpoint inhibitors on immune cells results in the inability of immune cells to destroy cancer cells. Checkpoint inhibitors block the interaction between ligands on the surface of cancer cells and checkpoint inhibitors, and allow immune cells to destroy cancer cells carrying ligands.

[0030] As used herein, the term "PD-1 inhibitor" means an inhibitor of programmed death protein ligand 1 (PD1), which is a checkpoint inhibitor expressed on the surface of T cells and B cells. Exemplary and non-limiting PD-1 inhibitors include pembrolizumab, nivolumab, cemiplimab, and dotalimumab.

[0031] As used herein, the term "recurrent cancer" means the growth of cancer cells that occurs in a subject after the subject has received cancer treatment. Cancer recurrence may be a local recurrence if the cancer occurs again in the same place where it was originally found, a regional recurrence if the cancer occurs again in lymph nodes near where the cancer was originally found, or a distant recurrence if the cancer occurs again in a different part of the body where the cancer was originally found.

[0032] As used herein, the term "refractory cancer" is a cancer that does not respond to first-line treatment (eg, standard of care) or that relapses after an initial response.

[0033] As used herein, the term "standard of care" refers to the treatment that a reasonably prudent physician would administer to a subject suffering from a disease or disorder.

[0034] As used herein, the term "carcinoma" refers to cancers that originate in the skin or in the tissues lining or covering internal organs.

[0035] As used herein, the term "lymphoma" refers to cancers that originate in the cells of the immune system.

[0036] As used herein, the term "leukemia" refers to cancers that originate in blood cells or blood-forming tissues.

[0037] As used herein, the term "sarcoma" refers to cancers that originate in bone or soft tissues of the body, including cartilage, fat, muscle, blood vessels, fibrous tissue, connective tissue, or supporting tissue.

[0038] As used herein, "enteric coating" is one or more polymer materials that envelop a drug core (e.g., a drug core containing N1-pyrrolidine-N5-(3-trifluoromethoxy)phenylbiguanide (a compound of Formula 1) or a pharmaceutically acceptable salt thereof) when passing through the stomach. Suitable pH-sensitive polymers are polymers that dissolve in intestinal fluids such as in the small intestine at higher pH levels (pH greater than 4.5), and thus allow pharmacologically active substances to be released in the small intestinal region rather than in the upper part of the gastrointestinal tract (such as the stomach). Enteric coatings also protect the stomach from irritating drug ingredients. Enteric coatings can be applied to a variety of formulations, including tablets, capsules, and microparticles. Enteric coatings can be applied directly to the drug core and can be an integral part of the tablet, capsule, or microparticle. Alternatively, the enteric coating can be separate from the drug core, wherein the coating is not attached to the drug core when encapsulating the drug core.

[0039] As used herein, "delayed release" means a pharmaceutical preparation, for example, an orally administered formulation, which passes substantially intact through the acidic environment of the stomach and dissolves in the more alkaline environment of the small intestine. In some embodiments, the delayed release of the active agent (e.g., N1-pyrrolidine-N5-(3-trifluoromethoxy)phenyl biguanide (a compound of Formula 1) or a pharmaceutically acceptable salt thereof) is caused by the use of a pH-sensitive enteric coating of an oral dosage form. The enteric coating can be combined with, for example, a delayed release formulation to extend the time period of drug release.

[0040] As used herein, "effective amount" means an amount of an agent sufficient to achieve a beneficial or desired result (such as disease alleviation) in a patient, and therefore, an "effective amount" depends on the context in which it is used, including the age and weight of the patient, the nature of the disease (including one or more organs affected by the disease), the disease state or activity level, and other factors.

[0041] As used herein, "pharmaceutically acceptable salts" means salts that are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reaction, etc., and commensurate with a reasonable benefit / risk ratio within the scope of reasonable medical judgment. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: Berge et al., J. Pharmaceutical Sciences 66: 1-19, 1977 and Pharm aceutical Salts: Properties, Selection, and Use, (P. H. Stahl and C. G. Wermuth, eds.), Wiley-VCH, 2008. These salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or prepared separately by reacting the free base groups with suitable organic or inorganic acids. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, bitartrate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, dodecanoate, dodecylsulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate, and the like. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations, including but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. In one embodiment, the pharmaceutically acceptable salt is acetate.

[0042] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Methods and materials for use in the present disclosure are described herein; other suitable methods and materials known in the art may also be used. These materials, methods, and examples are illustrative only and are not intended to be limiting. All publications, patent applications, patents, sequences, data entries, and other references mentioned herein are incorporated by reference in their entirety. In the event of a conflict, the present specification, including definitions, will prevail.

[0043] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will become apparent from the description and from the claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Figure 1A Figure 2 shows pre- and post-treatment biopsies for 84 unique cancer therapies.

[0045] Figure 1B is a graph showing an increase in OXPHOS in post-treatment biopsies relative to pre-treatment biopsies and an uncommensurate increase in glycolysis in post-treatment biopsies relative to pre-treatment biopsies.

[0046] Figure 1C is a graph showing increase in OXPHOS after leuprolide treatment in breast and prostate cancer.

[0047] Figure 1D is a graph showing increase in OXPHOS following enzalutamide treatment in prostate cancer.

[0048] Figure 1E is a graph showing increase in OXPHOS following treatment with fulvestrant, letrozole, and palbociclib in breast cancer.

[0049] Figure 1F is a graph showing increase in OXPHOS following cyclophosphamide treatment in breast cancer and sarcoma.

[0050] Figure 1G is a graph showing increase in OXPHOS following carboplatin treatment in breast, endometrial, non-small cell lung cancer (NSCLC), and ovarian cancers.

[0051] Figure 1H is a graph showing increase in OXPHOS following doxorubicin treatment in bladder cancer, breast cancer, and sarcoma.

[0052] Fig. 1I is a graph showing increase in OXPHOS after paclitaxel treatment in breast cancer, endometrial cancer, NSCLC, and ovarian cancer.

[0053] Figure 1J is a graph showing increase in OXPHOS after temozolomide treatment in glioblastoma.

[0054] Figure 2 is a graph showing that exposure of patient-derived xenograft cells to gemcitabine in vitro sensitizes tumor cells to the compound of Formula 1.

[0055] Figure 3 is a graph showing that the combination of the compound of Formula 1 and gemcitabine prolongs animal survival.

[0056] Figure 4A are micrographs showing the expression of pAMPK in cells that were untreated or treated with the compound of Formula 1.

[0057] Figure 4B are micrographs showing HIF-1a expression in cells that were untreated or treated with the compound of Formula 1.

[0058] Figure 5 A Phase 2 clinical study protocol is described to evaluate the use of a compound of Formula 1 in combination with standard of care (SOC) for the treatment of BRAF mutant metastatic melanoma.

[0059] Figure 6 A Phase 1b / 2a clinical study protocol is described to evaluate the use of a compound of Formula 1 in combination with standard of care (SOC) for the treatment of pancreatic ductal adenocarcinoma.

[0060] Fig. 7A is a graph showing the response of glioblastoma patient-derived cell subtypes to the compound of Formula 1.

[0061] Figure 7B is a graph showing the different responses of MTC and GPM cell subtypes to the compound of Formula 1.

[0062] Figure 8 A Phase 2 clinical study protocol is described to evaluate the use of a compound of Formula 1 in the treatment of patients with glioblastoma or BRAF mutant melanoma and brain metastases.

[0063] Fig. 9 A Phase 2 clinical study protocol is described to evaluate the use of a compound of Formula 1 in combination with standard of care (SOC) for the treatment of castration-resistant prostate cancer.

[0064] Fig.10 is a graph depicting the therapeutic window of compounds of Formula 1. DETAILED DESCRIPTION

[0065] The inventors have found that cancer cells with high oxidative phosphorylation (OXPHOS) levels can survive treatment with therapeutic agents that target metabolic pathways other than OXPHOS, and can relapse in subjects after treatment with therapeutic agents that do not target OXPHOS. Therefore, the present invention provides methods for treating cancer in subjects in need thereof with OXPHOS inhibitors.

[0066] OXPHOS inhibitors

[0067] OXPHOS is a metabolic pathway that involves the oxidation of chemical bonds in molecules (e.g., glucose) and results in the generation of adenosine triphosphate (ATP). The methods of the present invention include the use of all OXPHOS inhibitors, e.g., substances that inhibit proteins in the OXPHOS pathway, e.g., enzymes that catalyze chemical reactions in the OXPHOS metabolic pathway, and substances that inhibit protein expression in the OXPHOS metabolic pathway.

[0068] Exemplary and non-limiting OXPHOS inhibitors that can be used according to the methods of the invention include biguanides (e.g., metformin, phenformin or buformin), BAY84-243, carboxyamide triazole (CAI), fenofibrate, meta-iodobenzylguanidine (mIBG), pyrvinium, canagliflozin, pioglitazone, rosiglitazone, amobarbital, nefazodone, αTOS, lonidamine, atovaquone, arsenic trioxide, nitric oxide, hydrocortisone or uncoupling protein (UCP) (e.g., UCP1, UCP2, UCP3, UCP4 or UCP5) or derivatives or conjugates thereof.

[0069] In some embodiments, the OXPHOS inhibitor is a compound of Formula 1 (N-1-pyrrolidine-N-5-(3-trifluoromethoxy)phenylbiguanide) or a pharmaceutically acceptable salt thereof.

[0070]

[0071] Methods for synthesizing compounds of Formula 1 are disclosed in US Pat. No. 9,540,325, which is incorporated herein by reference in its entirety.

[0072] Any suitable OXPHOS inhibitor (e.g., an OXPHOS inhibitor having an ionizable functional group) can be administered as a pharmaceutically acceptable salt, such as a salt of an acid selected from the group consisting of formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid, trifluoroacetic acid, malic acid, maleic acid, malonic acid, fumaric acid, succinic acid, succinic acid monoamide, glutamic acid, tartaric acid, oxalic acid, citric acid, glycolic acid, glucuronic acid, ascorbic acid, benzoic acid, phthalic acid, salicylic acid, anthranilic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, dichloroacetic acid, aminooxyacetic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid, and boric acid.

[0073] Treatment

[0074] OXPHOS inhibitors can be used to treat cancer.Cancer is a group of diseases characterized by harmful, abnormal, uncontrolled and undesirable cell growth.In some embodiments, uncontrolled growth is due to the division and proliferation of cells in the absence of signals (e.g., growth factors) to instruct them to divide and proliferate.In some embodiments, uncontrolled growth is due to the inability of cells to respond to signals indicating that they stop growing and / or to participate in programmed cell death (i.e., apoptosis).In some embodiments, cancer cells can spread throughout the body (i.e., metastasis).In some embodiments, cancer cells can form tumors.In some embodiments, cancer cells can form solid tumors.

[0075] Without wishing to be bound by theory, the following description of treating cancer with OXPHOS inhibitors is provided. In some embodiments, the metabolic activity of cancer cells (e.g., Krebs cycle and oxidative phosphorylation (OXPHOS) activity) is unique to the metabolic activity of non-cancerous cells (e.g., Krebs cycle and OXPHOS activity). In some embodiments, OXPHOS inhibitors target the unique metabolic activity of cancer cells. In some embodiments, the unique metabolic activity of targeting cancer cells allows OXPHOS inhibitors to selectively kill cancer cells rather than non-cancerous cells.

[0076] In some embodiments, the total population of cancer cells (e.g., the total population of cancer cells in a subject, the total population of cancer cells in an organ, the total population of cancer cells in a biological tissue, or the total population of cancer cells in a cancer cell sample) can be composed of multiple subpopulations of cancer cells with different metabolic activities. One subpopulation of cancer cells may rely on OXPHOS to meet its metabolic needs, while a second subpopulation of cancer cells may not rely on OXPHOS to meet its metabolic needs, but may rely on alternative metabolic pathways, for example, glycolysis.

[0077] In some embodiments, treating a cancer cell population (e.g., a cancer cell population in a subject) with a therapeutic agent that is not an OXPHOS inhibitor can target only cancer cells that are not dependent on OXPHOS, and can result in killing only cancer cells that are not dependent on OXPHOS. In some embodiments, treating a cancer cell population with a therapeutic agent that targets a metabolic pathway other than OXPHOS can result in the growth of cancer cells that are dependent on OXPHOS, e.g., the recurrence of OXPHOS-dependent cancer cells in a subject.

[0078] In some embodiments, treating a population of cancer cells with a therapeutic agent that does not target OXPHOS and a therapeutic agent that targets OXPHOS (ie, an OXPHOS inhibitor) can result in killing of both OXPHOS-dependent and OXPHOS-independent cancer cells.

[0079] In some embodiments, a therapeutic agent that does not target OXPHOS and a therapeutic agent that targets OXPHOS can be administered sequentially. In some embodiments, a therapeutic agent that does not target OXPHOS and a therapeutic agent that targets OXPHOS can be administered concurrently.

[0080] In some embodiments, OXPHOS inhibitors can be used to treat the recurrence of cancer cells, for example, the recurrence of OXPHOS-dependent cancer cells that survived treatment with a therapeutic agent that does not target OXPHOS. In some embodiments, treating a cancer cell population simultaneously with a therapeutic agent that targets OXPHOS and a therapeutic agent that does not target OXPHOS results in killing of OXPHOS-dependent cancer cells and cancer cells that do not rely on OXPHOS. In some embodiments, treating a cancer cell population simultaneously with a therapeutic agent that targets OXPHOS and a therapeutic agent that does not target OXPHOS prevents the recurrence of cancer cells, for example, the recurrence of OXPHOS-dependent cancer cells.

[0081] Therefore, an effective amount of an OXPHOS inhibitor can be administered to a subject to treat cancer. Non-limiting examples of cancers that can be treated with an OXPHOS inhibitor or a pharmaceutically acceptable salt thereof include carcinomas, sarcomas, leukemias (e.g., acute lymphocytic leukemia, chronic lymphocytic leukemia, myeloid leukemia, or chronic myeloid leukemia) and lymphomas (e.g., Hodgkin's lymphoma or non-Hodgkin's lymphoma). In some embodiments, cancer is a solid tumor. In some embodiments, cancer is a metastatic tumor. Specific types of cancer that may be treated with an OXPHOS inhibitor, or a pharmaceutically acceptable salt thereof, include breast cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, rectal cancer, uterine cancer, vaginal cancer or vulvar cancer, testicular cancer, kidney cancer, liver cancer, bile duct cancer, cholangiocarcinoma, gallbladder cancer, melanoma, pancreatic cancer, pancreatic ductal adenocarcinoma, BRAF mutant metastatic melanoma, prostate cancer, castration-resistant prostate cancer, thyroid cancer, glioblastoma, endometrial cancer, ovarian cancer, cervical cancer, brain cancer, glioblastoma, liver cancer, colorectal cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, gynecological cancer, head and neck cancer, mesothelioma, myeloma, esophageal cancer, and gastric cancer.

[0082] Pancreatic ductal adenocarcinoma

[0083] Pancreatic ductal adenocarcinoma (PDAC) is an aggressive form of pancreatic cancer that occurs in the lining of the pancreatic ducts. PDAC is the most common form of pancreatic cancer and accounts for more than 90% of pancreatic malignancies worldwide. PDAC is the fourth most common cause of cancer-related deaths worldwide, and the 5-year overall survival rate is less than 8%.

[0084] BRAF mutant metastatic melanoma

[0085] Metastatic melanoma is a form of melanoma that has spread to multiple locations in the body other than the location where the melanoma originated. BRAF mutant metastatic melanoma is a form of metastatic melanoma in which the gene encoding the B-Raf protein (i.e., the BRAF gene) contains one or more mutations. BRAF mutations are the most common mutations in metastatic melanoma. Metastatic melanomas with BRAF mutations may be more aggressive than metastatic melanomas without BRAF mutations. BRAF mutant metastatic melanomas may metastasize to the brain.

[0086] Glioblastoma

[0087] Glioblastoma (GBM) is an invasive form of cancer that may occur in the brain or spinal cord and originates from glial cells. The 5-year overall survival rate for subjects diagnosed with GBM and receiving standard of care is less than 7%, and the median length of survival for subjects diagnosed with GBM is estimated to be 12 to 18 months.

[0088] Castration-resistant prostate cancer

[0089] Castration-resistant prostate cancer is a form of prostate cancer that continues to grow even when the amount of testosterone in the subject is reduced to very low levels (e.g., even after surgery or medical castration). The estimated average survival of subjects diagnosed with castration-resistant prostate cancer is approximately 9 to 36 months, and the quality of life of subjects diagnosed with castration-resistant prostate cancer and receiving standard of care is very poor.

[0090] Compositions for combination therapy

[0091] The OXPHOS inhibitor or a pharmaceutically acceptable salt thereof can be administered to a subject with or without a second active ingredient. Non-limiting examples of second active ingredients for treating cancer that can be administered with the OXPHOS inhibitor include lapatinib, Temozolomide Irinotecan Olaparib Doxorubicin Temsirolimus Gemcitabine Erlotinib Carboplatin Paclitaxel Bevacizumab Ipilimumab Gefitinib Apatinib, Vandetanib Sorafenib Dabrafenib Vemurafenib Fulvestrant Apelles Pabocini Letrozole Trastuzumab Pertuzumab Nelfinavir Bortezomib Disulfiram Ritonavir Memantine Hydrochloride Mefloquine Chloroquine, metronomic cyclophosphamide, liposomal doxorubicin Docetaxel (Taxotere), rituximab Cyclophosphamide, vincristine Prednisone Everolimus Exemestane Temsirolimus Sapacertin, rapamycin trametinib Sintilimab Nivolumab Durvalumab Pembrolizumab Rosiglitazone Pharmaceutical composition

[0092] OXPHOS inhibitors can be applied by any suitable means leading to cancer treatment.OXPHOS inhibitors can be included in any suitable carrier material in any suitable amount, and are generally present in an amount of 1%-95% (by weight) of the total weight of the composition.The composition can be provided in a dosage form suitable for sublingual, buccal, oral, parenteral (e.g., intravenous, intramuscular), pulmonary, intranasal, transdermal, vaginal or rectal administration.Therefore, the composition can be in the following forms: for example, tablets, capsules, pills, powders, granules, suspensions, emulsions, solutions, gels (including hydrogels), pastes, ointments, creams, plasters, infusions, osmotic delivery devices, suppositories, enemas, injections, sprays, steam agents or aerosols.Pharmaceutical compositions can be prepared according to conventional pharmaceutical practices (see, for example, Remington: The Science and Practice of Pharmacy, (23rd edition) A. Adejare. Edited, 2020, Academic Press, Philadelphia, PA).

[0093] The pharmaceutical compositions according to the present invention can be formulated to release the active compound substantially immediately after administration or at any predetermined time or time period after administration. Compositions of the latter type are generally referred to as controlled release formulations, which include (i) formulations that produce a substantially constant concentration of the active compound in vivo over an extended period of time; (ii) formulations that produce a substantially constant concentration of the active compound in vivo over an extended period of time after a predetermined lag time; and (iii) formulations that maintain the action of the active compound (sawtooth kinetic pattern) during a predetermined period of time by maintaining a relatively constant, effective level of the active compound in vivo while minimizing the undesirable side effects associated with fluctuations in the plasma level of the active compound.

[0094] In order to obtain the controlled release of the active compound in question, any of a number of strategies can be employed. In one example, controlled release is obtained by appropriately selecting various formulation parameters and ingredients (including, for example, various types of controlled release compositions and coatings). Therefore, the drug is formulated into a pharmaceutical composition together with a suitable excipient, which releases the active compound in a controlled manner after administration. Examples include single or multiple unit tablets or capsule compositions, oil solutions, suspensions, emulsions, microcapsules, microspheres, nanoparticles, patches, and liposomes.

[0095] The pharmaceutical compositions contemplated by the present invention may be an OXPHOS inhibitor or a pharmaceutically acceptable salt thereof mixed with a non-toxic pharmaceutically acceptable excipient. Pharmaceutically acceptable excipients are known to the skilled artisan. Excipients may be, for example, inert diluents or fillers such as sucrose, sorbitol, sugar, mannitol, microcrystalline cellulose (particularly microcrystalline cellulose PH101 or microcrystalline cellulose PH200), starch (including potato starch), calcium carbonate, sodium chloride, lactose, calcium phosphate, calcium sulfate or sodium phosphate; disintegrants such as crospovidone, sodium alginate, colloidal magnesium, aluminum silicate, calcium silicate, sodium starch glycolate, acrylic acid derivatives, microcrystalline cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, modified cellulose gum, cross-linked polyvinylpyrrolidone, alginic acid and alginates, pregelatinized Starch, modified corn starch cellulose derivatives (including microcrystalline cellulose), starch (including potato starch), cross-linked sodium carboxymethyl cellulose, alginates or alginic acid; binders such as sucrose, glucose, sorbitol, gum arabic, alginic acid, gelatin, starch, pregelatinized starch, microcrystalline cellulose, magnesium aluminum silicate, sodium carboxymethyl cellulose, methylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose EXF, ethylcellulose, polyvinyl pyrrolidone or polyethylene glycol; lubricants and / or glidants such as colloidal silicon dioxide (particularly colloidal silicon dioxide Cab-O- M5P), Tribehenyl Glyceryl, Magnesium Stearate, Calcium Stearate, Talc, Sodium Stearoyl Fumarate, Sodium Behenate, Stearic Acid, Cetyl Alcohol, Polyethylene Glycol, Leucine, Sodium Benzoate, Stearate, Polyethylene Glycol, Glyceryl Monostearate, Glyceryl Palmitate Stearate, Liquid Paraffin, Poloxamer, Sodium Lauryl Sulfate, Magnesium Lauryl Sulfate, Hydrogenated Castor Communis Colloidal Silica, Palmitostearate, Stearic Acid, Stearic Acid Zinc stearate, stearyl alcohol, silicon dioxide or hydrogenated vegetable oil; anti-caking agent, such as colloidal silicon dioxide, microcrystalline cellulose, tricalcium phosphate, microcrystalline cellulose, magnesium stearate, sodium bicarbonate, sodium ferrocyanide, potassium ferrocyanide, calcium ferrocyanide, calcium phosphate, sodium silicate, colloidal silicon dioxide, calcium silicate, magnesium trisilicate, talc, sodium aluminosilicate, potassium aluminum silicate, calcium aluminosilicate, bentonite, aluminum silicate, stearic acid, polydimethylsiloxane. Other pharmaceutically acceptable excipients can be colorants, flavoring agents, plasticizers, humectants and buffers.

[0096] dose

[0097] The dosage of the OXPHOS inhibitor (e.g., an OXPHOS inhibitor having a structure of Formula I) used in the methods described herein can vary according to many factors, such as the age, health and weight of the recipient; the nature and extent of the symptoms; the frequency of treatment and the type of concurrent treatment (if any); and the clearance rate of the compound in the animal to be treated. A person skilled in the art can determine a suitable dosage based on the above factors. The composition used in the methods described herein can be initially administered at a suitable dosage (which can be adjusted as needed, depending on the clinical response). Generally, a suitable daily dose of a compound of the present invention is the amount of the lowest dose at which the compound effectively produces a therapeutic effect. This effective dose will generally depend on the above factors.

[0098] While the attending physician will ultimately determine the appropriate amount and dosing regimen, the effective amount of the compositions of the present invention can be determined by the subject's body weight. For example, the effective amount can be between about 8 mg once daily (QD) and about 6,400 mg QD, for example, between about 8 mg QD and about 3,200 mg QD, between about 8 mg QD and about 3,200 mg QD, between about 8 mg QD and about 1,200 mg QD, between about 8 mg QD and about 800 mg QD, for example, between about 16 mg QD and about 400 mg QD, between about 32 mg QD and about 200 mg QD, between about 64 mg QD and about 100 mg QD, between about 100 mg QD and about 400 mg QD, between about 200 mg QD and about 300 mg QD, between about 400 mg QD and about 1,200 mg QD, between about 600 mg QD and about 1,000 mg QD, between about 700 mg QD and about 900 mg QD, between about 750 mg QD and about 800 mg QD. A solid dosage form or composition described herein of between about 100 mg QD and about 850 mg QD. In some embodiments, the effective amount can be between 8 mg QD ± 0.8 mg QD and 6,400 mg QD ± 640 mg QD, between 8 mg QD ± 0.8 mg QD and 3,200 mg QD ± 320 mg QD, between 8 mg QD ± 0.8 mg QD and 2,400 mg QD ± 240 mg QD, between 8 mg QD ± 0.8 mg QD and 1,200 mg QD ± 160 mg QD, between 8 mg QD ± 0.8 mg QD and 800 mg QD ± 80 mg QD, between 16 mg QD ± 1.6 mg QD and 400 mg QD ± 40 mg QD, between 32 mg QD ± 3.2 mg QD and 200 mg QD ± 20 mg QD, between 64 mg QD ± 6.4 mg QD and 100 mg QD ± 10 mg QD, between 100 mg QD ± 10 mg QD, and between 100 mg QD ± 10 mg QD. A solid dosage form or composition described herein between QD and 400 mg QD±40 mg QD, between 200 mg QD±20 mg QD and 300 mg QD±30 mg Qd, between 400 mg QD±40 mg and 1,200 mg QD±120 mg, between 600 mg QD±60 mg and 1,000 mg QD±100 mg, between 700 mg QD±70 mg and 900 mg QD±90 mg, between 750 mg QD±75 mg and 850 mg QD±80 mg.In some embodiments, the effective amount can be a solid dosage form or composition described herein between 8 mg QD and 6,400 mg QD, between 8 mg QD and 3,200 mg QD, between 8 mg QD and 2,400 mg QD, between 8 mg QD and 1,200 mg QD, between 8 mg QD and 800 mg QD, between 16 mg QD and 400 mg QD, between 32 mg QD and 200 mg QD, between 64 mg QD and 100 mg QD, between 100 mg QD and 400 mg QD, between 200 mg QD and 300 mg QD, between 400 mg QD and 1,200 mg QD, between 600 mg QD and 1,000 mg QD, between 700 mg QD and 900 mg QD, between 750 mg QD and 850 mg QD.

[0099] In some embodiments, it can be a solid dosage form or composition described herein at a dose of about 8 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dose of about 16 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dose of about 32 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dose of about 64 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dose of about 100 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dose of about 200 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dose of about 300 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dose of about 400 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dose of about 800 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dose of about 1,200 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dose of about 2,400 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dose of about 3,200 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dose of about 6,400 mg QD.

[0100] In some embodiments, it can be a solid dosage form or composition described herein at a dosage of 8mg QD±0.8mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dosage of 16mg QD±1.6mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dosage of 32mg QD±3.2mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dosage of 64mg QD±6.4mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dosage of 100mg QD±10mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dosage of 200mg QD±20mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dosage of 300mg QD±30mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dosage of 400mg QD±40mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dose of 800 mg QD ± 80 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of 1,200 mg QD ± 120 mg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of 2,400 mg QD ± 240 mg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of 3,200 mg ± 320 mg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of 6,400 mg ± 640 mg.

[0101] In some embodiments, it can be a solid dosage form or composition described herein at a dose of 8 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dose of 16 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dose of 32 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dose of 64 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dose of 100 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dose of 200 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dose of 300 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dose of 400 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dose of 800 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dose of 1,200 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dosage of 2400 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dosage of 3200 mg QD. In some embodiments, it can be a solid dosage form or composition described herein at a dosage of 6400 mg QD.

[0102] In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of about 1 mg / kg to about 80 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of about 1 mg / kg to about 40 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of about 3 mg / kg to 30 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of about 5 mg / kg to about 25 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of about 10 mg / kg to about 20 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of about 12 mg / kg to about 18 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of about 1.25 mg / kg to about 15 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of about 2.5 mg / kg to about 10 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of about 5 mg / kg to about 8 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of 1 mg / kg ± 0.1 mg / kg to 80 mg / kg ± 8300.0 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of 1 mg / kg ± 0.1 mg / kg to 40 mg / kg ± 4.0 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of 3 mg / kg ± 0.3 mg / kg to a solid dosage form or composition described herein at a daily dose of 30 mg / kg ± 3 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of 5 mg / kg ± 0.5 mg / kg to about 25 ± 2.5 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of 10 mg / kg ± 1.0 mg / kg to about 20 ± 2 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of 12 mg / kg ± 1.2 mg / kg to 18 mg / kg ± 1.8 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of 1.25 ± 0.125 mg / kg to 15 ± 1.5 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of 2.5 mg / kg ± 0.25 to 10 ± 1.0 mg / kg.In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of 5 ± 0.5 mg / kg to 8 ± 0.8 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of 1 mg / kg to 40 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of 3 mg / kg to 30 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of 5 mg / kg to 25 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of 10 mg / kg to 20 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of 12 mg / kg to 18 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of 1.25 mg / kg to 15 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of 2.5 mg / kg to 10 mg / kg. In some embodiments, it can be a solid dosage form or composition described herein at a daily dose of 5 mg / kg to 8 mg / kg. In some embodiments, it can be a daily dose of about 30 mg / kg. In some embodiments, it can be a daily dose of about 50 mg / kg. In some embodiments, it can be a daily dose of about 60 mg / kg.

[0103] Release curve

[0104] The controlled release composition for oral use can be configured to release the active drug by controlling the dissolution and / or diffusion of the active drug. In order to obtain the relationship curve between controlled release and target plasma concentration and time, any of many strategies can be adopted. In one example, controlled release is obtained by appropriately selecting various formulation parameters and ingredients (including, for example, various types of controlled release compositions and coatings). Examples include single or multiple unit tablets or capsule compositions, oil solutions, suspensions, emulsions, microcapsules, microspheres, nanoparticles, patches and liposomes. In certain embodiments, the composition comprises a biodegradable, pH and / or temperature-sensitive polymer coating (e.g., enteric coating). Dissolution or diffusion-controlled release can be achieved by appropriately coating the tablets, capsules, pills or granule formulations of the compound, or by incorporating the compound into a suitable matrix. The controlled release coating can include one or more of the above-mentioned coating materials.

[0105] Enteric coating is applied to the multiple technology of pharmaceutical composition is known in the art.In a non-limiting example, tablet and / or capsule can experience the drum coating process, wherein they roll in a cylindrical drum, while being sprayed by coating solution.In other non-limiting examples, tablet and / or capsule can experience the fluidized bed coating process, wherein air passes through tablet or capsule with enough speed to separate tablet and / or capsule into separate units, at this moment, tablet / capsule is sprayed with coating solution from top (for example, top spray coating), from below (for example, bottom spray coating) or from side (for example, HP spray coating).The amount of coating is determined by the amount of the solution sprayed.Coating can be applied in a single application, or can be constructed by using repeatedly applying in the form of multilayer.

[0106] Solid dosage forms for oral administration

[0107] Pharmaceutical compositions contemplated by the present invention include those formulated for oral administration ("oral dosage forms"). Oral dosage forms may be in the form of, for example, tablets, capsules, liquid solutions or suspensions, powders, or liquid or solid crystals, containing one or more active ingredients mixed with non-toxic pharmaceutically acceptable excipients. These compositions may be prepared in a variety of ways well known in the pharmaceutical art, and may release OXPHOS inhibitors, e.g., compounds of Formula 1, or pharmaceutically acceptable salts thereof, in specific sections of the gastrointestinal tract at controlled times by a variety of excipients and formulation techniques. For example, formulations may be customized to address specific diseases, to achieve the plasma levels of OXPHOS inhibitors (e.g., compounds of Formula 1) required to achieve therapeutic efficacy, to achieve the desired duration of drug effect, and to provide a group of compositions with different drug releases.

[0108] OXPHOS inhibition

[0109] A variety of techniques for measuring OXPHOS inhibition are well known in the art.Exemplary and non-limiting methods for measuring OXPHOS inhibition are described below.

[0110] Measurement of mitochondrial complex I inhibition

[0111] The electron transfer complex in mitochondria is composed of 5 complexes. Complex I accepts the electrons of NADH produced from glycolysis and TCA cycle, and the electrons move to complex II, III and IV, and the electrons are finally transferred to O2 and generate water molecules. During electron transfer, a proton gradient is generated, and the chemical gradient is the driving source for synthesizing ATP at complex V. The mitochondrial inhibition of complex I is indirectly assessed by measuring the oxygen consumption rate (OCR) at complex IV. When mitochondrial ETC is inhibited, glycolysis is upregulated and lactic acid production increases. When lactic acid is transported to the extracellular, the extracellular solution becomes acidic (lower pH). OCR and extracellular acidification rate (ECAR) are measured by XF analyzer (Seahorse Biosciences). Therefore, the OXPHOS inhibitory effect (for example, the OXPHOS inhibitory effect caused by the compound of Formula I) on cell (such as cancer cell) sample can be measured by measuring the oxygen consumption rate of cell sample or the extracellular acidification rate of cell sample.

[0112] Cytotoxicity assay under low glucose conditions

[0113] Inhibition of oxidative phosphorylation (OXPHOS) is not cytotoxic to cells under normal glucose conditions, as normal cells are assumed to have compensatory mechanisms under energy stress conditions such as low glucose. However, OXPHOS inhibitors show cytotoxic effects on cells under glucose deprivation conditions. Glucose deprivation conditions observed in the tumor microenvironment may be due to poor angiogenesis. Therefore, OXPHOS inhibitors may have anticancer effects on cancer cells under low glucose conditions that can delineate the tumor microenvironment.

[0114] Equivalent content and scope

[0115] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments of the invention described herein.The scope of the present invention is not intended to be limited to the above description.

[0116] The following examples are illustrative only and are not intended to limit the invention in any way.

[0117] Example

[0118] Example 1. Pre- and post-treatment biopsies of patients undergoing cancer therapy

[0119] Collect biopsies from subjects undergoing cancer treatment ( Figure 1A Cells captured in post-treatment biopsies utilized OXPHOS more than cells captured in pre-treatment biopsies and utilized glycolysis less than cells captured in pre-treatment biopsies ( Figure 1B-1J ).Discover:

[0120] 1) ENO1 and SLC45A1 expression are not robust biomarkers of OXPHOS, each showing positive and negative correlations in different cancer types.

[0121] a) Single copy loss (LOH) of the locus is associated with higher OXPHOS levels, especially in cholangiocarcinoma, where it is prevalent (approximately 33%)

[0122] 2) Pan-cancer gene-based analysis identified 7 genes with higher pathogenic mutation burden associated with increased OxPhos pathway scores (FDR < 5%) - STK11, CDH1, PRKAR1A, KEAP1, TSC2, MAP3K1, and PIK3CA

[0123] 3) Single variant analysis in each cancer tested identified 7 variants associated with increased OxPhos scores (FDR < 10%) with moderate effect sizes - AKT1, TP53 (2 variants), STAG2, PIK3CA, KMT2C, and MTOR

[0124] 4) Single variant meta-analysis across cancers identified 2 variants in the genes RET and TP53 that were detected to contribute to more than one cancer

[0125] 5) Most therapies appear to increase OXPHOS (or select for clones with high OXPHOS levels)

[0126] a) In particular, leuprolide, enzalutamide, fulvestrant, letrozole, palbociclib, cyclophosphamide, carboplatin, doxorubicin, paclitaxel, and temozolomide were the most notable therapies.

[0127] Example 2. Evaluation of the combination of Formula 1 and gemcitabine in the treatment of pancreatic ductal adenocarcinoma.

[0128] Patient-derived xenograft cells ( Figure 2 ). Cells treated with both Gem and Formula 1 grew slower than cells treated with Formula 1 or Gem alone.

[0129] Animals with pancreatic ductal adenocarcinoma were treated with a compound of Formula 1, Gem, or a combination of a compound of Formula 1 and Gem ( Figure 3 ). Animals treated with the combination of Gem and the compound of Formula 1 survived longer than animals treated with Gem or the compound of Formula 1 alone.

[0130] The expression of the mechanism of action biomarkers pAMPK and HIF-1a in untreated cells versus cells treated with the compound of Formula 1 supports that the combination of Gem and Compound 1 inhibits cancer cell growth and prolongs survival (Figures 4a and 4b).

[0131] Example 3. Clinical study of the combination of Formula 1 and standard of care for the treatment of BRAF mutant metastatic melanoma in human subjects.

[0132] Subjects with BRAF mutant metastatic melanoma were enrolled in a Phase 2 clinical study to evaluate the effectiveness of the combination of the compound of Formula 1 and standard of care (SOC) in treating BRAF mutant metastatic melanoma ( Figure 5 Dose escalation and dose selection were determined with an initial cohort of 20 subjects who were administered a combination of SOC, BRAFi (encofenib, 450 mg PO QD) and MEKi (bimetinib, 45 mg PO BID) with a compound of Formula 1 (increasing doses from 100 mg to 200 mg to 400 mg to 800 mg).

[0133] After determining the dose of the compound of Formula 1, the cohort was expanded to 100 subjects. One group was administered BRAFi, MEKi, and the compound of Formula 1, and the second group was administered BRAFi and MEIKi.

[0134] The primary endpoints were ORR and PFS. Secondary endpoints were safety, tolerability, and OS.

[0135] Example 4. Clinical Study of Combination of Formula 1 and Standard of Care for the Treatment of Pancreatic Ductal Adenocarcinoma in Human Subjects

[0136] Subjects with pancreatic ductal adenocarcinoma were enrolled in a clinical study to evaluate the effectiveness of the combination of a compound of Formula 1 and standard of care (SOC) in treating pancreatic ductal adenocarcinoma ( Figure 6 ). Dose escalation and dose selection were determined using an initial cohort of 12 subjects who were administered a combination of a SOC of gemcitabine and nab-paclitaxel with a compound of Formula 1 (400 mg > 800 mg).

[0137] After the dose of the compound of Formula 1 was determined, the cohort was expanded to 13 subjects. One group was administered SOC + the compound of Formula 1 at the determined dose. The comparison group was derived from existing MDACC data from patients with similar characteristics to those enrolled in this study.

[0138] The primary endpoints were safety and tolerability. Secondary endpoints were ORR, PFS, and OS.

[0139] Example 5. Evaluation of the response of glioblastoma patient-derived cell subtypes to the compound of Formula 1.

[0140] Treatment of glioblastoma patient-derived cell subtypes ( Fig. 7A ). Compared with the GPM cell subtype, the MTC GBM cell subtype is more sensitive to treatment with the compound of Formula 1 ( Figure 7B ).

[0141] Example 6. Clinical study of a compound of Formula 1 in combination with standard of care for the treatment of BRAF mutant metastatic melanoma in human subjects

[0142] A Phase 0 go / no-go (window of opportunity) study in 12-24 subjects newly diagnosed with GBM was conducted to evaluate brain penetration and effects on biomarkers of the compound of Formula 1. Figure 8 ).

[0143] Subjects (N=60) newly diagnosed with GBM with the MTC subtype were enrolled in a study to evaluate the effectiveness of a combination of a compound of Formula 1 and SOC (which is radiation / temozolomide) in treating GBM with the MTC subtype. One group was administered SOC alone, and a second group was administered a combination of SOC and a compound of Formula 1.

[0144] Subjects with BRAF mutant melanoma and brain metastases (N=20) were enrolled in a study to evaluate the effectiveness of the compound of Formula 1 in treating BRAF mutant melanoma and brain metastases. The compound of Formula 1 was administered to the subjects at a selected MTD dose.

[0145] The primary endpoints for both the study of subjects with GBM with the MTC subtype and the study of patients with BRAF-mutant melanoma and brain metastases were ORR and OFS. Secondary endpoints were safety, tolerability, and OS.

[0146] Example 7. Clinical study of the combination of Formula 1 and standard of care for the treatment of castration-resistant prostate cancer

[0147] Subjects (N=30) were enrolled in a clinical study to evaluate the effectiveness of the combination of a compound of Formula 1 and SOC (which is a CBI / PD-1 inhibitor) in the treatment of castration-resistant prostate cancer ( Fig. 9 ). One group was administered SOC + compound of formula 1. One group was administered SOC alone. The primary endpoints were ORR and PFS. The secondary endpoints were safety, tolerability, and OS.

[0148] Example 8. Therapeutic Window of Compounds of Formula 1

[0149] The therapeutic window of the compound of Formula 1 is determined for various indications ( Fig.10 ).

[0150] Other Implementations

[0151] Various modifications and variations of the present invention described will be clear to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in conjunction with specific embodiments, it should be understood that the claimed invention should not be unduly limited to such specific embodiments. In fact, various modifications of the described modes for implementing the present invention that are obvious to those skilled in the art are intended to fall within the scope of the present invention.

[0152] All references, patents, patent application publications, and patent applications mentioned herein are hereby incorporated by reference in their entirety.

[0153] Other embodiments are within the claims.

Claims

1. A method of treating cancer in a subject, the method comprising administering to the subject an oxidative phosphorylation (OXPHOS) inhibitor, wherein the cancer is refractory or recurrent to first-line therapy.

2. The method of claim 1, wherein the first-line treatment is the standard of care for the cancer.

3. The method of claim 1 or 2, wherein the cancer is carcinoma, sarcoma, leukemia or lymphoma.

4. The method of any one of claims 1-3, wherein the cancer is a solid tumor.

5. The method of any one of claims 1-4, wherein the cancer is a metastatic cancer.

6. The method of claim 3, wherein the leukemia is acute lymphocytic leukemia, chronic lymphocytic leukemia, myeloid leukemia, or chronic myeloid leukemia.

7. The method of claim 3, wherein the lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma.

8. The method of claim 3, wherein the cancer is breast cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, rectal cancer, uterine cancer, vaginal cancer or vulvar cancer, testicular cancer, kidney cancer, liver cancer, biliary tract cancer, bile duct cancer, gallbladder cancer, melanoma, pancreatic cancer, pancreatic ductal adenocarcinoma, BRAF mutant metastatic melanoma, prostate cancer, castration-resistant prostate cancer, thyroid cancer, glioblastoma, endometrial cancer, ovarian cancer, cervical cancer, brain cancer, glioblastoma, liver cancer, colorectal cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, gynecological cancer, head and neck cancer, mesothelioma, myeloma, esophageal cancer, or gastric cancer.

9. The method of any one of claims 1 to 8, wherein the OXPHOS inhibitor is a compound of the following formula 1 or a pharmaceutically acceptable salt thereof 10. The method of claim 9, wherein the compound of Formula 1 is formulated as a tablet or a capsule.

11. The method of claim 9, wherein the tablet or capsule is formulated for delayed release.

12. The method of claim 10 or 11, wherein the tablet or capsule comprises an enteric coating.

13. The method of any one of claims 9-12, wherein the compound of Formula 1 is administered at a dose of about 100 mg, 200 mg, 400 mg, 800 mg or 1200 mg per day.

14. The method of claim 13, wherein the compound of Formula 1 is administered at a dose of about 800 mg per day.

15. The method of any one of claims 1-9, wherein the OXPHOS inhibitor is administered in combination with a second therapeutic compound.

16. A method for treating pancreatic ductal adenocarcinoma (PDAC), the method comprising administering a pharmaceutical composition to a subject in need thereof at a therapeutically effective dose, wherein the composition comprises a compound of Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient 17. The method of claim 16, wherein the compound of Formula 1 is administered in combination with gemcitabine and nab-paclitaxel.

18. A method for treating BRAF mutant melanoma, the method comprising administering a pharmaceutical composition to a subject in need thereof at a therapeutically effective dose, wherein the composition comprises a compound of the following formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient 19. The method of claim 18, wherein the compound of Formula 1 is administered in combination with encofenib and bimetinib.

20. The method of claim 18 or 19, wherein the BRAF mutant melanoma is metastatic.

21. The method of claim 20, wherein the metastasis is to the central nervous system.

22. The method of claim 20 or 21, wherein the metastasis is to the brain.

23. The method of claim 22, wherein the method comprises the use of radiation and / or the administration of temozolomide.

24. A method for treating castration-resistant prostate cancer (CRPC), the method comprising administering a pharmaceutical composition to a subject in need thereof at a therapeutically effective dose, wherein the composition comprises a compound of the following formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient 25. The method of claim 24, wherein the subject has not responded to at least one line of immunotherapy.

26. The method of claim 24 or 25, wherein the compound of Formula 1 is administered in combination with a checkpoint inhibitor.

27. The method of claim 26, wherein the checkpoint inhibitor is a PD-1 inhibitor.

28. The method of any one of claims 16-27, wherein the compound of Formula 1 is formulated as a tablet or a capsule.

29. The method of claim 28, wherein the tablet or capsule is formulated for delayed release.

30. The method of claim 28 or 29, wherein the tablet or capsule comprises an enteric coating.

31. The method of any one of claims 16-30, wherein the compound of Formula 1 is administered at a dose of about 100 mg, 200 mg, 400 mg, 800 mg, or 1200 mg per day.

32. The method of claim 31, wherein the compound of Formula 1 is administered at a dose of about 800 mg per day.

33. The method of any one of claims 9-32, wherein the pharmaceutically acceptable salt is a salt of an acid selected from the group consisting of formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid, trifluoroacetic acid, malic acid, maleic acid, malonic acid, fumaric acid, succinic acid, succinic acid monoamide, glutamic acid, tartaric acid, oxalic acid, citric acid, glycolic acid, glucuronic acid, ascorbic acid, benzoic acid, phthalic acid, salicylic acid, anthranilic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, dichloroacetic acid, aminooxyacetic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid, and boric acid.

34. The method of claim 33, wherein the pharmaceutically acceptable salt is acetate.

35. The method of any one of claims 1-34, wherein the subject is a human.